NCT05426720 Risk Factors and Biomarkers for Post-tuberculosis Lung Damage
| NCT ID | NCT05426720 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Peking University Third Hospital |
| Condition | Pulmonary TB |
| Study Type | OBSERVATIONAL |
| Enrollment | 400 participants |
| Start Date | 2022-01-01 |
| Primary Completion | 2024-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 400 participants in total. It began in 2022-01-01 with a primary completion date of 2024-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This prospective study aims to determine the incidence of Post-tuberculosis lung damage (PTLD), examine trends in the changes in lung function, and investigate the impact of smoking and other factors on respiratory symptoms, lung function, and chest CT findings, which will aid in the development of prognostic and therapeutic strategies for PTLD.
Eligibility Criteria
Inclusion Criteria: Male patients aged 25-60 years newly diagnosed with active pulmonary TB. Exclusion Criteria: 1. patients with positive sputum smear or TB culture results; 2. human immunodeficiency virus-positive patients; 3. patients infected with multidrug-resistant TB; 4. patients with malignant neoplasms (e.g., lung cancer) or severe cardiovascular and cerebrovascular diseases; 5. non-compliant patients who were unable to complete the lung function tests; 6. patients without lung parenchymal destruction (such as tuberculous pleurisy). -
Contact & Investigator
Yongchang Sun, MD
STUDY DIRECTOR
Respiratory and Critical Care Department, Peking University Third Hospital
Frequently Asked Questions
Who can join the NCT05426720 clinical trial?
This trial is open to male participants only, aged 25 Years or older, up to 60 Years, studying Pulmonary TB. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05426720 currently recruiting?
Yes, NCT05426720 is actively recruiting participants. Contact the research team at gxy81wfl79@163.com for enrollment information.
Where is the NCT05426720 trial being conducted?
This trial is being conducted at Beijing, China, Beijing, China.
Who is sponsoring the NCT05426720 clinical trial?
NCT05426720 is sponsored by Peking University Third Hospital. The principal investigator is Yongchang Sun, MD at Respiratory and Critical Care Department, Peking University Third Hospital. The trial plans to enroll 400 participants.